The consensus price target hints at a 55% upside potential for Revance Therapeutics (RVNC). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
The average of price targets set by Wall Street analysts indicates a potential upside of 98.6% in Revance Therapeutics (RVNC). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
(Reuters) -Anti-wrinkle injection maker Revance Therapeutics has agreed to be bought by privately held Crown Laboratories in a deal valued at $924 million, including debt, seeking scale to compete better with rivals in the aesthetic products market. Revance manufactures Daxxify, which competes with AbbVie's Botox, while Tennessee-based Crown makes various skincare and aesthetics products like SkinPen for microneedling and anti-aging cream StriVectin. Revance, which promotes its product to last twice as long as Botox, had initially priced it at a premium.